Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus carboplatin and paclitaxel vs placebo plus carboplatin and paclitaxel in first-line metastatic or advanced NSCLC
2011-003427-36Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Veliparib + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Feb 2012; status: completed.
02
Drugs
veliparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-003427-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003427-36.